Women executives who reach the top in finance are reshaping the profession while creating newfound value for their companies, ...

Innovative research at Weill Cornell Medicine introduces engineered mycobacteria strains with 'kill switches' for safer TB ...

Working toward more effective tuberculosis (TB) vaccines, researchers at Weill Cornell Medicine have developed two strains of mycobacteria with "kill switches" that can be triggered to stop the ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

India's CRDMO sector has the potential to reach USD 22-25 billion by 2035, driven by supply chain de-risking, pricing ...

Developed by the Serum Institute of India, the rBCG product, which has been modified to improve its immunogenicity and safety, was evaluated in phase 1/2 clinical trials in Europe in patients with ...

Coding assistance and completion tools saved developers around 4 million hours last year, the retailer recently told ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

A new LNP-mRNA vaccine significantly boosts immune response and enhances BCG protection against tuberculosis, offering a ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

The students, thereafter, knocked at the doors of Gujarat HC which ordered the BCG to issue the certificate to the students ...

India currently holds a 2-3 per cent share of the USD 140-145 billion global CRDMO market but has the potential to become a ...